What is "lampalizumab"

Lampalizumab ( INN) is an antigen-binding fragment of a humanized monoclonal antibody designed for the treatment of geographic atrophy secondary to age-related macular degeneration. It binds to CFD.

Enrollment in Phase 3 clinical trials has been initiated. Phase 3 trials are usually conducted in order to establish the effectiveness of a drug, and compare the results to known alternative treatments.